Authors: Jani, Ashesh B.; Gratzle, John

Source: American Journal of Cancer, Volume 5, Number 3, 2006 , pp. 193-198(6)

Publisher: Adis International

Abstract:

Background: Hormone therapy is commonly used with radiotherapy in the treatment of prostate cancer.

Aim: To provide a single-institution analysis of the benefits of hormone therapy with radiotherapy in different non-metastatic prostate cancer scenarios.

Methods: The records of 527 patients receiving radiotherapy for locally advanced, localized, and post-prostatectomy disease were reviewed. For the 422 patients with localized disease, biochemical failure-free survival curves were generated for patients receiving or not receiving hormone therapy (with biochemical failure defined as three successive rises after prostate-specific antigen nadir). The survival curves were compared using the log-rank test and a multivariate analysis of all major patient, disease, and treatment factors was performed. Additionally, failure rates were compared using the chi-square test to determine the benefit of hormone therapy across each of the locally advanced, localized, and post-prostatectomy settings.

Results: An advantage for the use of hormone therapy compared with radiotherapy alone was observed in the population with localized disease (3-year biochemical failure-free survival 78% vs 75%; p = 0.029). Of the patient, disease, and treatment factors analyzed, only clinical T-stage (p = 0.002), radiation dose (p = 0.006), and hormone therapy (p = 0.016) reached statistical significance on multivariate analysis. Furthermore, lower failure rates occured (with at least a trend observed [p < 0.10]) in patients receiving hormone therapy in each clinical scenario, with the exception of the localized low-risk subgroup.

Conclusion: In a single-institution analysis, the addition of hormone therapy to radiotherapy was advantageous in all settings of non-metastatic prostate cancer except that of the very earliest disease presentation.

Keywords: Bicalutamide; Flutamide; Gonadotropin releasing hormone agonists; Goserelin; Hormones; Leuprorelin; Prostate cancer; Radiotherapy; Testosterone antagonists

Document Type: Research article

Affiliations: 1: Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, Illinois, USA

Publication date: 2006-01-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Oncology
• By this author: Jani, Ashesh B. ;  Gratzle, John

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers